Torben Plesner

Lifeline:

Born on 28. February 1947.

Medical Degree: University of Copenhagen, Copenhagen, Denmark.

First part: 1968. Second part: 1972.

Doctor of Medical Sciences at the University of Copenhagen 1981. Thesis title: "Immunochemical Studies of Human β2-Microglobulin. A Review of Recent Methodological Progress and Clinical Ap­plications".

Certified as clinical chemistry (MD) Specialist in Denmark, 1981.

Certified as internal medicine Specialist in Denmark, 1989.

Certified as hematology Specialist in Denmark, 1990.

1. March 1993 - 30. September 2000: Consultant of Hematology, Herlev Hospital, University Hospital, Copenhagen.

From 1. October 2000 – 31. December 2024: Consultant of Hematology, Section of Internal Medicine, Vejle Hospital, and from 1. March 2009 – 31. December 2024 Clinical Professor of Hematology, University of Southern Denmark, Institute of Regional Health Science.

From 1. January 2025 Professor Emeritus, University of Southern Denmark, Institute of Regional Health Science.

Scientific profile:

I have published 152 scientific articles that are indexed in PubMed.

ISI Web of Science has 134 hits for scientific articles with 8574 citations giving an average of 58 citations per item and an “H-index” of 44.

See also: https://scholar.google.com/citations?user=ShMcuGEAAAAJ.

Thesis accepted by University of Copenhagen July 1981 in fulfillment of Doctor of Medical Sciences degree.

Thesis title: "Immunochemical Studies of Human β2-Microglobulin. A Review of Recent Methodological Progress and Clinical Ap­plications".

Lines of research, GCP training and experience from Clinical Trials:

-       Immunochemical Studies of Human β2-Microglobulin with development of the first radioimmunoassay of β2-Microglobulin.

-       Development of monoclonal antibodies to human leukocyte antigens and participation in the Clusters of Differentiation (CD) Workshops and development program.

-       Development of a diagnostic test for Paroxysmal Nocturnal Hemoglobinuria (PNH) by flow cytometry and studies of the Urokinase-type Plasminogen Activator Receptor (UPAR) in PNH.

-       Development of new therapies in multiple clinical trials with a focus on immunotherapy of multiple myeloma. Dosed the first myeloma patient with Daratumumab in March 2008.